Formulation

Nov 17, 2016
By BioPharm International Editors
Avecia is adding drug substance capacity at its Milford, MA manufacturing site.
Nov 01, 2016
BioPharm International
Interactions between biologic drug products and the components of prefilled syringes can cause protein aggregation, but there are alternative materials that can help mitigate this problem.
Nov 01, 2016
BioPharm International
The development of mAb formulations poses challenges at the manufacturing, stability, analytical, and administration levels.
Oct 20, 2016
By BioPharm International Editors
Prefilled syringes for commercial supply of the etanercept biosimilar will be produced at Catalent’s Brussels facility in Belgium.
Oct 01, 2016
BioPharm International
An approach to stabilize PBS-based formulations could provide a simple physiological solution for use of proteins in research, preclinical, diagnostics, and clinical studies, as well as commercial biotherapeutic products.
Oct 01, 2016
BioPharm International
Challenging molecules and markets are driving the development of new solutions for drug delivery.
Oct 01, 2016
BioPharm International
Multiparticulates are increasingly used due to their flexibility in providing controlled-release, fixed-dose combinations, ease of taste-masking, and suitability for pediatric applications
Oct 01, 2016
BioPharm International
High-purity low-endotoxin sugars improve robustness and stability of protein formulation and improve drug product quality.
Jul 28, 2016
By BioPharm International Editors
NIST’s monoclonal antibody reference material can be used as a standard for biopharmaceutical analytical quality control.
Jul 28, 2016
Amgen discussed the drug-delivery approaches to two of its biologics in a recent second-quarter earnings call.
native1_300x100
lorem ipsum